Available Technology
Diagnostic test for Alzheimer's disease
Technology:
Clinical diagnostic test for detection and monitoring progression of Alzheimer's disease
Markets Addressed
Medical diagnostics
Innovations and Advantages
The invention employs a non-neurological indicator of Alzheimer's Disease (AD) to provide a simple diagnostic assay. Individuals who suffer from AD present progressive and, ultimately, fatal senile dementia. Post-mortem observation of neurofibrillary tangles and amyloid plaques in brain tissue typically yields the first conclusive diagnosis of AD, frustrating attempts at early disease intervention.
Abnormal ion exchange across red blood cell (RBC) membranes is known to accompany AD. According to the invention, blood samples are screened for a specific conformational shift in the protein underlying that defect. Significant advantages of the invention are:
- Use of non-neural test material.
- Suitability for risk assessment and/or early diagnosis of AD.
- Enables continuous monitoring of disease progression and the efficacy of prophylactic or therapeutic agents.
Additional Information
Intellectual Property Status: The invention is protected by U.S. Patent No. 6,030,768 and is available for exclusive license.
Tweet
Inventor(s):
Greco, Frank A.
Solomon, Arthur K.
Categories:
For further information, please contact:
Grant Zimmermann, Director of Business Development
(617) 495-3067
Reference Harvard Case #1386